AbZelectPRO™: Achieving High-Titer Productivity & Accelerated Timelines Cell Line Development Poster from AET 2025

At the Antibody Engineering and Therapeutics Conference in San Diego, our VP of Research & Innovation, Rob Holgate, presented a poster titled “AbZelectPRO: Achieving high-titer productivity & accelerated timelines with enhanced cell line platforms.”  The newly enhanced cell line development platform offers additions, including two GS Knockout cell lines (Revvity CHOSOURCE), increased productivity, proven performance, and rapid timelines, enabling biopharma customers to progress from DNA to RCB with flexibility and ease.

Abstract
Our fully integrated AbZelectPRO platform enables the rapid delivery of stable, high-producing cell lines to support the production of complex biologics. The platform combines our AbZelectPRO CHO-K1 and AbZelectPRO -KO GS knockout cell lines together with ProteoNic’s 2G UNic® premium vector technology and an optimised process to generate fast doubling, higher-producing, stable cell lines expressing up to 10 g/L of product, and DNA to RCB in as little as 10 weeks.

The AbZelectPRO platform supports a diverse range of modalities from antibodies and more difficult-to-express proteins such as fusion proteins, bispecifics, vaccines and other novel
modalities. Furthermore, the platform also allows for program derisking by using early material generation from stable pools to remove activities such as downstream method development and formulation development from the critical path. Backed by our comprehensive analytics portfolio, the AbZelectPRO platform simplifies the development process and helps to deliver therapeutic proteins successfully to the clinic.

Access the poster

Poster authors include: Brett Verstak*, Blanca San Miguel, Oscar Swindley , Nathan Courtier, Kean Huedepohl, Ned Swift, Miles Wellington, Sophie Douglas, Noah Collins, Elizabeth Willows, Tania Fisher, Kalpana Wood, Tanya Knight, Beata Blaszczyk, Nicole Wakes, Rob Holgate

Abzena has over two decades of expertise in developing over 200+ cell lines.  For more information about our robust and flexible cell line development capabilities, click here.